Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivopixant Phase 2b in Refractory Chronic Cough
NCT04110054Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of sivopixant in chronic cough (4 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment. Started Feb 2020; status: completed.
02
Drugs
sivopixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT04110054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110054.